RefleXion Announces Multi System Contract with Select Healthcare

August 30, 2022 — RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT), a new modality that uses emissions generated from the cancer itself to direct radiotherapy, announced a three-system contract with Select Healthcare, a developer of affiliated cancer facilities throughout the United States. The multi-year, multi-site contract will create new free-standing treatment centers that showcase the dual modality of the RefleXion X1 platform for treating all stages of cancer with external beam radiotherapy (EBRT). 

“The creation of these initial three new free-standing radiotherapy centers will bring RefleXion’s novel BgRT to local communities so that patients with solid tumor cancers can receive state-of-the-art cancer care near their home,” said Matthew Cutler, CEO, president and founder of Select Healthcare Solutions. “The X1 is the only system to offer breakthrough motion management for moving tumors using biological guidance and anatomic guidance for earlier stage cancers. We envision that this future capability will be attractive to our physician partners because it brings radiotherapy as a new treatment option to patients with late-stage cancer.” 

The RefleXion X1 machine with BgRT is designed to overcome the technical limitations that restrict radiotherapy to one or two tumors. Instead, it will one day allow radiotherapy to reach more tumors during the same treatment session, even those tumors that move due to patient motion, such as breathing or digestion. 

“We applaud the Select Healthcare vision of bringing advanced cancer care to patients being treated at the community level through the establishment of these new centers,” said Todd Powell, president and CEO of RefleXion. “As we move forward commercializing the X1 and our future release of BgRT, we are proud to count Select Healthcare among our early customers.” 

BgRT uses emissions from a patient’s cancer cells created by injecting a small amount of a targeting molecule carrying a positron-emitting radioisotope, known as a PET tracer, to guide EBRT. As the PET tracer binds to the tumor cells, it produces emissions that signal the cancer’s location. The RefleXion X1 machine design integrates PET arcs with a linear accelerator to detect these emissions and then direct radiotherapy to each tumor. 

For more information: www.reflexion.com